An observational study in Corneal Opacity, sponsored by Omar Said. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2023-08-21.
Sponsored by Omar Said · Observational
The purpose of this study is to assess the characteristics of trachomatous corneal opacity in patients with signs of trachoma using Anterior segment Optic coherence tomography and Pentacam
After approval of the local institutional ethics committee and local institutional review board, patient presented to Fayoum University Hospital was examined for corneal opacity with signs of trachoma after a detailed informed consent was signed by eligible patients and investigated by Anterior Segment Optic coherence Tomography and Pentacam.
Descriptive statistics were presented in the form of mean and standard deviation for numerical variables while numbers and percentages are used for the categorical variables.
Paired samples t-test was used to study anterior segment Optic Coherence tomography and pentacam in evaluating corneal thickness. Bland-Altman plot was used to study the agreement between the two methods IBM SPSS version 28 for Windows software was used for the analysis and Stata 16 was used for the Bland-Altman plot. A p-value of \< 0.05 was considered significant.
37 studies on the registry are indexed under Corneal Opacity; 5 are open to participants now.
This study's enrollment of 50 is above the median of 45 across 14 observational studies indexed under Corneal Opacity.
Browse Corneal Opacity studies →Omar Said is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with trachomatous corneal opacity
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
AS-OCT,PENTACAM
Corneal imaging
AS-OCT and PENTACAM in patients with trachomatous corneal opacity
Time frame: we will recruit patients who meer the inclusion criteria during the study period february-August 2022
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2022 to primary completion in Aug 2022, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Omar Said